Diligence memo · auto-generated · as of July 2, 2026

In-Pipe Technology Company, Inc.

In-Pipe Technology Company, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

In-Pipe Technology Company, Inc. operates in Biotechnology, based in Wheaton.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

In-Pipe Technology Company, Inc. has raised $7.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $5.0M on 2009-08-06.

Most recent recorded round closed around 2010-08-09.

Valuation (modeled)modeled

Provath models In-Pipe Technology Company, Inc. at approximately $72M (range $2.2M–$393M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.36× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 12 months.

Last raise 15.9 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.5× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 50% of Biotechnology peers (4293 compared).

Modeled value ranks above 53% of those peers.

Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.